← Back to Clinical Trials
Recruiting NCT07279545

NCT07279545 The Effect of Placental Cord Drainage on the Third Stage of Labor and the Amount of Postpartum Bleeding

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07279545
Status Recruiting
Phase
Sponsor Saglik Bilimleri Universitesi Gulhane Tip Fakultesi
Condition Postpartum Hemorrhage
Study Type INTERVENTIONAL
Enrollment 80 participants
Start Date 2025-11-17
Primary Completion 2026-06-20

Eligibility & Interventions

Sex Female only
Min Age 18 Years
Max Age 35 Years
Study Type INTERVENTIONAL
Interventions
Placental cord drainage

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 80 participants in total. It began in 2025-11-17 with a primary completion date of 2026-06-20.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The aim of the study was to evaluate the effect of controlled placental cord drainage by opening the clamp at the maternal end after the umbilical cord is cut during birth on the duration of the third stage of labor (departure of the placenta), the amount of blood loss in the third stage, the amount of bleeding in the 2nd hour postpartum, and the development of postpartum complications.

Eligibility Criteria

Inclusion Criteria: * No problem speaking and understanding Turkish * Low-risk pregnant women * Vertex presentation * 37-41st weeks of gestation * There are no complications in the mother or the baby that prevent normal birth. * The VAS score for the pain felt by the pregnant woman at the time of admission to the study must be less than 3 (to show that the pregnant women were accepted into the study at a time when their pain was at its lowest and their decision-making ability was at a relatively good level) Exclusion Criteria: * History of postpartum hemorrhage * History of postpartum hemorrhage in mother or sister * Birth interval less than 2 years * Anticoagulant use during pregnancy * Smoking during pregnancy * Those with low Hb values (Hb\<11gr/dL) * Hematocrit \<30

Contact & Investigator

Central Contact

Sinem GÜLTEKİN, Phd

✉ sinemgultekin06@gmail.com

📞 05546531112

Principal Investigator

Ferhat TÜFEKÇİ, Spc. Dr.

PRINCIPAL INVESTIGATOR

Zonguldak Maternity and Child Diseases Hospital

Frequently Asked Questions

Who can join the NCT07279545 clinical trial?

This trial is open to female participants only, aged 18 Years or older, up to 35 Years, studying Postpartum Hemorrhage. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07279545 currently recruiting?

Yes, NCT07279545 is actively recruiting participants. Contact the research team at sinemgultekin06@gmail.com for enrollment information.

Where is the NCT07279545 trial being conducted?

This trial is being conducted at Zonguldak, Turkey (Türkiye).

Who is sponsoring the NCT07279545 clinical trial?

NCT07279545 is sponsored by Saglik Bilimleri Universitesi Gulhane Tip Fakultesi. The principal investigator is Ferhat TÜFEKÇİ, Spc. Dr. at Zonguldak Maternity and Child Diseases Hospital. The trial plans to enroll 80 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology